Allert H. Vos

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

Jolien Tol, Miriam Koopman, Annemieke Cats et al. · New England Journal of Medicine · 2009 · 1.3K citations · Full text

Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents

J. Tol, Miriam Koopman, Michael Craig Miller et al. · Annals of Oncology · 2009 · 212 citations

Overall Survival, Medicine, Pathology +7

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

J. Tol, Miriam Koopman, C. J. Rodenburg et al. · Annals of Oncology · 2008 · 208 citations

Cairo2 Study, Interim Analysis, Oncology +7

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial

Vivianne C. G. Tjan‐Heijnen, Irene E.G. van Hellemond, Petronella G.M. Peer et al. · The Lancet Oncology · 2017 · 157 citations

Medicine, Clinical Trials, Gynecology +10

Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)

C.J.A. Punt, J. Tol, C. J. Rodenburg et al. · Journal of Clinical Oncology · 2008 · 130 citations

Cancer Management, Immunology, Pathology +20